Date: 14 August, 2018 **Sydney, Australia**

NOXOPHARM CORPORATE PRESENTATION

FNN – SHAW&PARTNERS INVESTOR EVENT

Sydney, 14 August 2018: Noxopharm (ASX:NOX) is pleased to provide its Corporate Presentation for tomorrow's (Wednesday 15th August – 12pm-2:30pm) FNN- Shaw&Partners Investor Event at the Radisson Blu Hotel, O'Connell St, Sydney.

The presentation can also be found by visiting the Noxopharm website (www.noxopharm.com)

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of resistance in cancer cells to radiotherapy and chemotherapy, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates including idronoxil-C under development. The Company also has an expanding pipeline of non-oncology drugs.

Investor & Corporate Enquiries:

Prue Kelly

M: 0459 022 445
info@noxopharm.com

Company Secretary :

David Franks

T: +61 2 9299 9690
E: dfranks@fa.com.au

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe",

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office and Operations Office:
Suite 3, Level 4
828 Pacific Highway
Gordon NSW 2072
Australia

“continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

NOXOPHARM

ASX: NOX



Discover

Develop

Deliver

Corporate objective

To bring to market in 2022
the first approved **radio-enhancer**
that boosts the the effect of radiotherapy

NOX66

- Potently
- Safely
- Cost-effectively

Radio-enhancement



- Radiation ‘burns’ DNA strands
- Cell attempts to repair damage
- If repair successful, cell survives (but at risk of further cancer)
- If repair unsuccessful, cell dies

AIM =

- Block repair of DNA damage
- Applied dose of radiotherapy kills more cancer cells



Locally invasive curative Rx



Palliative symptomatic Rx

Radio-enhancement



Previous attempts to develop a radio-enhancing drug:

- Aimed at blocking DNA repair
- (PARP-1 inhibitors)
- No repair = cell dies

Unsuccessful because:

- Also block DNA repair in healthy cells
- Unacceptable toxicity



NOX66

- First-in-class dual-action radio-enhancer:
  1. Blocks cell division – DNA more susceptible to radiation
  2. Blocks repair of DNA damage
- BUT ONLY IN CANCER CELLS
- NO KNOWN EFFECT ON HEALTHY CELLS
- NO KNOWN TOXICITY WHEN USED WITH RADIOTHERAPY
- Increases killing effect of radiation by 2-3 times
- Effective pre-clinically with prostate, lung, breast, brain cancer cells

Initial clinical use of NOX66

NOXOPHARM

Compassionate case #1

- Late-stage prostate cancer
- Tumours in spine, lymph nodes, bone
- NOX66 + palliative radiotherapy to spinal and LN tumours
- 10-week scan = complete response in irradiated tumours
- Complete response in all other (non-irradiated) tumours
- Remains cancer-free after 4 years



	7/7/14	29/9/14	28/11/14	2/3/15	30/4/15
Total PSA	140	170	13	0.18	0.07

Initial clinical use of NOX66

Compassionate case #2

- Leiomyosarcoma
- Primary in abdomen
- Secondaries in lungs
- NOX66 + palliative radiotherapy to primary lesion only
- Partial shrinkage of lung secondary tumours
- Patient remains well and symptom-free 12 months later



Prior to NOX66 + radiotherapy



3 months after NOX66 + radiotherapy

'Abscopal Effect'

- Irradiation of a selected tumour leads to response in distant tumours
- Extremely rare phenomenon
- Introduction of immuno-oncology drugs (PD-1/PD-L1 drugs) and GM-CSF has increased occurrence …..
- …. indicating involvement of an immune response



- Radiation kills cancer cells
- Cancer (non-self) antigens released
- Immune cells activated
- Activated immune cells able to attack non-irradiated cancer cells

Radio-enhancement: *DIRECT and ABSCOPAL*





Direct response



Partial abscopal response



Complete abscopal response

Abscopal-inducing drugs

	Radiotherapy only	Enhanced response in irradiated tumours	+ abscopal response
Assume a patient with multiple tumours: *2 tumours are irradiated*			
Clinical benefit			
Symptoms (pain)	+	+++	+++
Quality of Life	+	++	+++
Time to disease progression	+	++	++++
Overall survival	+	++	++++

NOX66: *Immuno-oncology drug*

Confirmed:

NOX66 increases activity of natural killer (NK) cells.

NK cells are the body's first line of defence against cancer cells



Radio-enhancement capability comparison

	NOX66	PD-1/PD-L1 drugs
Direct radio-enhancement	YES	NO
Wide cancer spectrum	YES Target on all cancer cells	Monotherapy effect limited to certain tumor types
Well tolerated	No dose-limiting toxicities known	Dose-limiting toxicities (eg bowel perforation) known
Duration of treatment	2-3 weeks	Open-ended. Continue until toxicity of disease progression
Affordability	Indicative affordable cost	$150,000 list price

DARRT-1 Clinical Study

- Late-stage prostate cancer
  - Metastatic castrate-resistant disease
  - no remaining treatment options
- Eligible for palliative radiotherapy for symptom relief
- Radiotherapy for 5 days
- NOX66 for 14 days



Cohort 1: 4 patients. 400 mg NOX66

Cohort 2: 4 patients. 800 mg NOX66

Cohort 3: 4 patients. 1200 mg NOX66

Cohort 4: 12 patients. optimal dose of NOX66

Tumour assessment at:

- 6-weeks
- 12-weeks
- 24-weeks

DARRT-1 Clinical Study: *interim data*

DARRT-1: *Anticipated data read-out timetable*



DARRT Program Strategy 2019

Multinational study (up to 50 sites)

Planning has commenced:
- CRO appointed
- Advisory Board met

Projected start mid-2019
Projected completion mid-2021



What I haven't mentioned ……..

- **Lu-PSMA program** in late-stage prostate cancer. Phase 1b 16-man study. (*Fully recruited*)
- **CEP (chemo-sensitising) program**
- **2nd generation IDRONOXIL** dosage formulation studies

Key metrics

Shares outstanding	**122M** : 91M free + 31M escrowed (May 2019)
Other	22.5M options ($0.30) (2021)
Market Cap	$73M
IPO price (Aug 2016) **Last traded**	20 cents 60 cents
Cash position	AU$ 11.9M (30 June 2018)



Key Investment Messages

- AUSTRALIAN SCIENCE
- MANAGEMENT EXPERIENCED IN DRUG DEVELOPMENT AND PUBLIC COMPANIES
- TRACK RECORD OF INVESTOR RELATIONS AND CAPITAL RAISINGS
- SUFFICIENTLY FUNDED TO RUN CURRENT PHASE 1/2 PROGRAMS
- A SUCCESSFUL OUTCOME IS A SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET

✓ Lean operation
✓ Experienced team

✓ A number of key inflection points anticipated within next 12 months

✓ NOX66 potential blockbuster drug

Disclaimer

- *This presentation has been prepared by Noxopharm Limited (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events an actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after th date of this presentation document which may affect any matter referred to in the presentation.*

Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com

NOXOPHARM